BLA 103795 · Immunex
Enbrel
Etanercept · Subcutaneous · Tumor Necrosis Factor Blocker
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Oct 14, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1998
Nov 2, 1998
Approved uses
21
Original approval plus efficacy supplements
Registered trials
373
108 Phase 3, 17 recruiting
FAERS reports
597,166
216,189 serious, 17,505 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS INFECTIONS and MALIGNANCIES WARNING: SERIOUS INFECTIONS and MALIGNANCIES See full prescribing information for complete boxed warning. SERIOUS INFECTIONS Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens. ( 5.1 ) Enbrel should be discontinued if a patient develops a serious infection or sepsis during treatment. ( 5.1 ) Perform test for latent TB; if positive, start treatment for TB prior to starting Enbrel. ( 5.1 ) Monitor all patients for active TB during treatment, even if initial latent TB test is negative. ( 5.1 ) MALIGNANCIES Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF-blockers, including Enbrel. ( 5.3 ) SERIOUS...
What it is approved for
From the label in effect May 11, 2026.
Enbrel is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Adult patients with: Rheumatoid Arthritis (RA) ( 1.1 ) Psoriatic Arthritis (PsA) ( 1.3 ) Ankylosing Spondylitis (AS) ( 1.4 ) Plaque Psoriasis (PsO) ( 1.5 ) Pediatric patients with: Polyarticular Juvenile Idiopathic Arthritis (pJIA), 2 years of age or older ( 1.2 ) Juvenile Psoriatic Arthritis, 2 years of age or older (JPsA) ( 1.6 ) Plaque Psoriasis, 4 years of age or older ( 1.5 ) 1.1 Rheumatoid Arthritis Enbrel is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (RA). Enbrel can be initiated in combination with methotrexate (MTX) or used alone. 1.2 Polyarticular Juvenile Idiopathic Arthritis Enbrel is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older. 1.3 Psoriatic Arthritis Enbrel is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in adult patients with psoriatic arthritis (PsA). Enbrel can be used with or without methotrexate. 1.4 Ankylosing Spondylitis Enbrel is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis (AS). 1.5 Plaque Psoriasis Enbrel is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy. 1.6 Juvenile Psoriatic Arthritis Enbrel is indicated for the treatment of active juvenile psoriatic arthritis (JPsA) in pediatric patients 2 years of age and...
Mechanism: TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. It plays an important role in the inflammatory processes of RA, polyarticular JIA, PsA, and AS and the resulting joint pathology. In addition, TNF plays a role in the inflammatory process of PsO. Elevated levels of TNF are found in involved tissues and fluids of patients with RA, JIA, PsA, AS, and PsO. Two distinct receptors for TNF (TNFRs), a 55 kilodalton protein (p55) and a 75 kilodalton protein (p75), exist naturally as monomeric molecules on cell surfaces and in soluble forms. Biological...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 18, 2023 Supplement 5595 · Efficacy LetterLabel
- Nov 22, 2017 Supplement 5559 · Efficacy Letter
- Sep 14, 2017 Supplement 5556 · Efficacy LabelLetter
- Nov 4, 2016 Supplement 5552 · Efficacy LetterLabel
- May 17, 2006 Supplement 5256 · Efficacy Orphan
- May 27, 2005 Supplement 5191 · Efficacy LetterLabel
- Sep 27, 2004 Supplement 5184 · Efficacy LabelLetter
- Sep 24, 2004 Supplement 5162 · Efficacy LabelLetter
- Apr 30, 2004 Supplement 5149 · Efficacy LetterLabel
- Nov 25, 2003 Supplement 5125 · Efficacy Letter
- Oct 17, 2003 Supplement 5110 · Efficacy Letter
- Aug 21, 2003 Supplement 5102 · Efficacy ReviewLetter
- Jul 24, 2003 Supplement 5097 · Efficacy ReviewLetter
- Jul 24, 2003 Supplement 5123 · Efficacy · priority review ReviewLetter
- Sep 12, 2002 Supplement 5051 · Efficacy Patient Package InsertLabelLetter
- Jan 15, 2002 Supplement 5034 · Efficacy · priority review LabelReviewLetter
- Jan 15, 2002 Supplement 5016 · Efficacy
- Jan 15, 2002 Supplement 5014 · Efficacy
- Jun 6, 2000 Supplement 1004 · Efficacy LetterLabel
- May 27, 1999 Supplement 1001 · Efficacy · priority review ReviewLetter
- Nov 2, 1998 Original approval · Type 1 - New Molecular Entity · priority review LabelOther Important Information from FDAPediatric Medical Review
2 products under this application
- ENBREL · ETANERCEPT 50MG/ML · SYRINGE, · Prescription
- ENBREL · ETANERCEPT 25MG/VIAL · VIAL, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Etanercept" as an intervention, any sponsor and status, largest first.
- Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid ArthritisPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT02092467 · 4,372 participants · Start Mar 14, 2014 · Primary completion Jul 22, 2020
Drug: tofacitinib; tofacitinib and 2 more · For: Arthritis, Rheumatoid
Sites: Birmingham, Alabama; Huntsville, Alabama; Tuscaloosa, Alabama · 345 sites in all
- A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk FactorsPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01331837 · 3,080 participants · Start Aug 2, 2011 · Primary completion Mar 25, 2016
Drug: Etanercept; Tocilizumab · For: Rheumatoid Arthritis
Sites: Birmingham, Alabama; Huntsville, Alabama; Tuscaloosa, Alabama · 428 sites in all
- A Study of Baricitinib (LY3009104) in Participants With Rheumatoid ArthritisPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT03915964 · 2,659 participants · Start Apr 25, 2019 · Primary completion May 28, 2025
Drug: Baricitinib; TNF Inhibitor · For: Rheumatoid Arthritis
Sites: Flagstaff, Arizona; Gilbert, Arizona; Glendale, Arizona · 261 sites in all
- A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)Pivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT01646177 · 1,346 participants · Start Jul 28, 2012 · Primary completion May 22, 2014
Drug: Placebo; 50 mg etanercept and 1 more · For: Psoriasis
Sites: Anaheim, California; Bakersfield, California; Bell Gardens, California · 101 sites in all
- Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type PsoriasisPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01358578 · 1,306 participants · Start Jun 2011 · Primary completion Jul 2013
Drug: Placebo; secukinumab (AIN457) and 1 more · For: Chronic Plaque Psoriasis
Sites: Birmingham, Alabama; Phoenix, Arizona; San Diego, California · 152 sites in all
- Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF TherapyPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT00124982 · 1,286 participants · Start Apr 2005 · Primary completion Aug 2009
Drug: Abatacept; Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD) and 1 more · For: Rheumatoid Arthritis
Sites: Birmingham, Alabama; Huntsville, Alabama; Paradise Valley, Arizona · 148 sites in all
- A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)Pivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT01597245 · 1,224 participants · Start May 18, 2012 · Primary completion Mar 25, 2014
Drug: 80 mg ixekizumab Dosing Regimen; 50 mg etanercept and 1 more · For: Psoriasis
Sites: Phoenix, Arizona; Scottsdale, Arizona; Little Rock, Arkansas · 118 sites in all
- A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque PsoriasisPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01241591 · 1,101 participants · Start Nov 2010 · Primary completion Jan 2013
Drug: CP 690,550 5 mg; CP 690,550 10 mg and 1 more · For: Psoriasis
Sites: Buenos Aires, Argentina; Feldkirch, Austria; Innsbruck, Austria · 122 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective75,667
- injection site pain56,857
- rheumatoid arthritis47,136
- arthralgia45,566
- pain43,715
- injection site erythema41,077
- fatigue30,777
- joint swelling25,864
- pain in extremity25,734
- psoriasis25,160
- headache25,036
- injection site swelling23,301
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,194 |
| 2005 | 1,836 |
| 2006 | 8,806 |
| 2007 | 17,520 |
| 2008 | 16,649 |
| 2009 | 14,437 |
| 2010 | 22,274 |
| 2011 | 29,182 |
| 2012 | 42,296 |
| 2013 | 46,953 |
| 2014 | 41,070 |
| 2015 | 57,540 |
| 2016 | 58,757 |
| 2017 | 59,690 |
| 2018 | 49,137 |
| 2019 | 30,610 |
| 2020 | 26,238 |
| 2021 | 17,083 |
| 2022 | 17,132 |
| 2023 | 13,528 |
| 2024 | 11,931 |
| 2025 | 7,857 |
| 2026 | 5,446 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Enbrel (Etanercept)
2024 spending
$633M
Beneficiaries
10,542
80,845 claims
Per beneficiary
$60,026
$1,804.19 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $583,367,035 |
| 2021 | $590,851,426 |
| 2022 | $612,015,042 |
| 2023 | $627,419,987 |
| 2024 | $632,791,431 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and network meta-analysis of randomized clinical trials.
Spencer RK, Jin JQ, Elhage KG, et al. · J Am Acad Dermatol 2023 · Letter, Network Meta-Analysis
- Secukinumab in plaque psoriasis--results of two phase 3 trials.
Langley RG, Elewski BE, Lebwohl M, et al. · N Engl J Med 2014 · Clinical Trial, Phase III, Multicenter Study
- Small-Molecule Inhibitors and Biologics for Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta-Analysis.
Huang IH, Wu PC, Chiu HY, et al. · Am J Clin Dermatol 2024 · Systematic Review, Comparative Study
- Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial.
Giles JT, Sattar N, Gabriel S, et al. · Arthritis Rheumatol 2020 · Comparative Study, Randomized Controlled Trial
- Risk of new-onset and recurrent uveitis with different biologics for ankylosing spondylitis: a network meta-analysis.
Zhao X, Xie Q, He X, et al. · Front Immunol 2025 · Network Meta-Analysis, Systematic Review
- Etanercept for treating axial spondyloarthritis.
Guillot X, Prati C, Sondag M, et al. · Expert Opin Biol Ther 2017 · Systematic Review
Sponsor: Immunex
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.